Categories: HealthcareNews

Senzime Appoints Former Dräger Medical CEO Wolfgang Reim as New Senior Advisor to The Board

UPPSALA, SE / ACCESSWIRE / May 17, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime, an industry leader in perioperative precision-based patient monitoring solutions, today announced the appointment of Dr. Wolfgang Reim as new senior advisor to its Board of Directors.

Wolfgang Reim has a long medical industry career including positions as CEO of the Ultrasound Division of Siemens Healthcare, CEO of Dräger Medical during 2000-2006, and many Board and Chairman roles in companies including Elekta AB, GN Store Nord, Carl Zeiss and Ondal Medical Systems. Wolfgang Reim was born in 1956, resides in Germany and has a MSc and Doctors degree in Physics from the Federal Institute of Technology ETH in Zurich.

“We’re honored to welcome Dr. Reim as senior advisor to Senzime. His global expertise, strong commercialization skills and experience in bringing world-class medical technologies to market will be highly beneficial to Senzime as we continue to execute our rapid growth journey”, commented Senzime’s CEO Philip Siberg.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime, headquartered in Sweden, is a leading medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. The company provides an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for accurate monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX: SNZZF). More information is available at senzime.com .

Attachments

Senzime appoints former Dräger Medical CEO Wolfgang Reim as new senior advisor to the board

SOURCE: Senzime

View the original press release on accesswire.com

Staff

Recent Posts

TODAY SHOW EXPOSES AI MEDICAL SCAMS TARGETING LIPEDEMA PATIENTS

LOS ANGELES, Dec. 5, 2025 /PRNewswire/ -- AI-generated deepfake scams are rapidly spreading across social media,…

1 minute ago

Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc.

Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / December 5, 2025…

3 hours ago

Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc.

Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / December 5, 2025…

3 hours ago

Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink:…

6 hours ago

Techficient Launches Surefire, Its Proprietary Modern Underwriting Engine

BOISE, Idaho, Dec. 5, 2025 /PRNewswire/ -- Techficient, a leading innovator in Insurtech solutions, announces the…

6 hours ago

Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications

Company brings its Scientific Activation™ mission to life at ASH Annual Meeting following November rebrand RESTON,…

6 hours ago